Abstract
This study compared a range of mammalian CNS expression cassettes in recombinant adeno-associated virus (AAV-2) vectors using strong endogenous promoter sequences, with or without a strong post-regulatory element and polyadenylation signal. Changes in these elements led to transgene expression varying by over three orders of magnitude. In experiments conducted in primary cell culture and in >100 stereotactically injected rats, we observed highly efficient and stable (>15 months) gene expression in neurons and limited expression in glia; the highest expression occurred with endogenous, nonviral promoters such as neuron-specific enolase and β-actin. The packaging size of AAV-2 was maximized at 5.7 kb without impairing gene expression, as judged by direct comparison with a number of smaller AAV-2 constructs. The genomic insert size and titer were confirmed by Southern blot and quantitative PCR, and infectivity was tested by particle titer using ELISA with a conformation-dependent epitope that requires the full intact capsid. A packaging and purification protocol we describe allows for high-titer, high-capacity AAV-2 vectors that can transduce over 2 × 105 neurons in vivo per microliter of vector, using the strongest expression cassette.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Douglas JT et al. A system for the propagation of adenoviral vectors with genetically modified receptor specificities Nat Biotechnol 1999 17: 470–475
Romanczuk H et al. Modification of an adenoviral vector with biologically selected peptides: a novel strategy for gene delivery to cells of choice Hum Gene Ther 1999 10: 2615–2626
Girod A et al. Genetic capsid modifications allow efficent re-targeting of AAV-2 Nat Med 1999 9: 1052–1056
Davidson B et al. Recombinant adeno-associated virus type 2, 4 and 5 vectors: transduction of variant cell types and regions in the mammalian cental nervous system Proc Natl Acad Sci USA 2000 97: 3428–3432
Kaplitt MG et al. Long-term gene expression and phenotypic correction using AAV vectors in the mammalian brain Nat Genet 1994 8: 148–154
Du B, Wu P, Boldt-Houle DM, Terwilliger EF . Efficient transduction of human neurons with an AAV vector Gene Therapy 1996 3: 254–261
McCown TJ et al. Differential and persistent expression patterns of CNS gene transfer by an AAV vector Brain Res 1996 713: 99–107
During MJ et al. Peroral gene therapy of lactose intolerance using an AAV vector Nat Med 1998 4: 1131–1135
During MJ et al. In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector Gene Therapy 1998 5: 820–827
Chamberlin NL, Du B, Lacalle SD, Saper CB . Recombinant AAV vector: use for transgene expression and anterograde tract tracing in the CNS Brain Res 1998 793: 169–175
Andersen JK, Garber DA, Meaney CA, Breakefield XO . Gene transfer into mammalian central nervous system using herpes simplex virus vectors: extended expression of bacterial lacZ in neurons using the neuron-specific enolase promoter Hum Gene Ther 1992 3: 487–499
Andersen JK, Frim DM, Isacson O, Breakefield XO . Herpesvirus-mediated gene delivery into the brain: specificity and efficiency of the neuron-specific enolase promoter Cell Mol Neurobiol 1993 13: 503–515
Doll RF et al. Comparison of promoter strengths on gene delivery into mammalian brain cells using AAV vectors Gene Therapy 1996 3: 437–447
Peel AL, Zolotukhin S, Schrimsher GW, Muzyczka N . Efficient transduction of green fluorescent protein in spinal cord neurons using AAV vectors containing cell type-specific promoter Gene Ther 1997 4: 16–24
Klein RL et al. Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant AAV vectors Exp Neurol 1998 150: 183–194
Chen H, McCarty DM, Bruce AT, Suzuki K . Gene transfer and expression in oligodendrocytes under the control of myelin basic protein transcriptional control region mediated by AAV Gene Therapy 1998 5: 50–58
Morelli AE et al. Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosis-inducing molecule Fas ligand to predetermined brain cell types, and abolish peripheral liver toxicity J Gen Virol 1999 80: 571–583
Wang Y, Yu L, Geller AI . Diverse stabilities of expression in the rat brain from different cellular promoters in a helper-virus-free herpes simplex virus type 1 vector system Hum Gene Ther 1999 10: 1761–1771
Hannas-Djebbara Z et al. Transgene expression of plasmid DNAs directed by viral or neural promoters in the rat brain Mol Brain Res 1997 46: 91–99
Podsakoff G, Wong KK, Chatterjee S . Efficient gene transfer into non-dividing cells by AAV-based vectors J Virol 1994 68: 5656–5666
Xiao X, Li J, McCown TJ, Samulski RJ . Gene transfer by AAV into the central nervous system Exp Neurol 1997 144: 113–124
Wu P, Phillips MI, Bui J, Terwilliger EF . AAV vector mediated transgene integration into neurons and other nondividing cell targets J Virol 1998 72: 5919–5926
Lo WD et al. AAV-mediated gene transfer to the brain: duration and modulation of expression Hum Gene Ther 1999 20: 201–213
Mizukami H, Young NS, Brown KE . AAV-2 binds to a 150kD cell membrane glycoprotein Virology 1996 217: 124–130
Duan D et al. Polarity influences the efficiency of recombinant AAV infection in differentiated airway epithelia Hum Gene Ther 1998 9: 2761–2776
Summerford C, Samulski RJ . Membrane-associated heparan sulfate proteoglycan is a receptor for AAV-2 virions J Virol 1998 72: 1438–1445
Ruffing M, Heid H, Kleinschmidt JA . Mutations in the carboxy terminus of AAV capsid proteins affect viral infectivity: lack of an RGD integrin-binding motif J Gen Virol 1994 75: 3385–3392
Summerford C, Barlett JS, Samulski RJ . aVb5 integrin: a co-receptor for AAV-2 infection Nat Med 1999 5: 78–81
Qing K et al. Human fibroblast growth factor receptor is a co-receptor for infection by AAV-2 Nat Med 1999 5: 71–77
Bartlett JS, Samulski RJ, McCown TJ . Selective and rapid uptake of AAV-2 in brain Hum Gene Ther 1998 9: 1181–1186
Linden RM, Woo SLC . AAVant-garde gene therapy Nat Med 1999 5: 21–22
Dong JY, Fan PD, Frizzell RA . Quantitative analysis of the packaging capacity of recombinant AAV Hum Gene Ther 1996 7: 2101–2112
Hermonat PL, Quirk JG, Bishop BM, Han L . The packaging capacity of AAV and the potential for wild-type-plus AAV gene therapy vectors FEBS Lett 1997 407: 78–84
Wang D et al. Efficient CFTR expression from AAV vectors packaged with promoters – the 2nd generation Gene Therapy 1999 6: 667–675
Huang ZM, Yen TS . Role of the hepatitis B virus posttranscritional regulatory element in export of intronless transcripts Mol Cell Biol 1995 15: 3864–3869
Donello J, Loeb JE, Hope TJ . Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element J Virol 1998 72: 5085–5092
Pfarr DS et al. Differential effects of polyadenylation regions on gene expression in mammalian cells DNA 1986 5: 115–122
Yew NS et al. Optimization of plasmid vectors for high-level expression in lung epithelial cells Hum Gene Ther 1997 8: 575–584
Blomer U et al. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector J Virol 1997 71: 6641–6649
McLachlan EM, Janig W . The cell bodies of origin of sympathetic and sensory axons in some skin and muscle nerves of the cat hindlimb J Comp Neurol 1983 214: 115–130
Zolotukhin S et al. Recombinant AAV virus purification using novel methods improves infectious titer and yield Gene Therapy 1999 6: 973–985
Qiu J, Mizukami H, Brown KE . AAV-2 co-receptors? Nat Med 1999 5: 467–468
Nurcombe V et al. Developmental regulation of neural response to FGF-1 and FGF-2 by heparan sulfate proteoglycan Science 1993 260: 103–106
Pinkstaff JK et al. Integrin subunit gene expression is regionally differentiated in adult brain J Neurosci 1999 19: 1541–1556
Bansal R et al. Development and FGF-2-mediated regulation of syndecans and glypican in oligodendrocytes Mol Cell Neurosci 1997 7: 276–288
Takami K et al. FGF-1 expression in the cortex and hippocampus in Alzheimer's Disease Brain Res 1998 802: 89–97
Tawil NJ et al. Expression and distribution of functional integrins in rat CNS glia J Neurosci Res 1994 39: 436–447
Duan D et al. Dynamin is required for recombinant AAV-2 infection J Virol 1999 73: 10371–10376
Qiu J, Brown KE . A 110kDa nuclear shuttle protein, nucleolin, specifically binds to AAV-2 capsid Virology 1999 257: 373–382
Qing K et al. AAV-2-mediated gene transfer: correlation of tyrosine phosphorylation of the cellular single-stranded D sequence-binding protein with transgene expression in human cells in vitro and murine tissues in vivo J Virol 1998 72: 1593–1599
Flotte TR et al. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an AAV vector Proc Natl Acad Sci USA 1993 90: 10613–10617
Twyman RM, Jones EA . Sequences in the proximal 5′ flanking region of the rat neuron-specific enolase (NSE) gene are sufficient for cell type-specific reporter gene expression J Mol Neurosci 1997 8: 63–73
Forss-Petter S et al. Transgenic mice expressing beta-galactosidase in mature neurons under neuron-specific enolase promoter control Neuron 1990 5: 187–197
Leone P et al. Global CNS gene transfer for a childhood neurogenetic enzyme deficiency: Canavan disease Curr Opin Mol Ther 1999 1: 487–492
Lachmann RH, Efstathiou S . Use of herpes simplex virus type 1 for transgene expression within the nervous system Clin Sci (Colch) 1999 96: 533–541
La Gamma EF et al. Dopaminergic regulation of a transfected preproenkephalin promoter in primary rat astrocytes in vitro and in vivo Exp Neurol 1994 130: 304–310
Clark KR et al. Highly purified recombinant AAV vectors are biologically active and free of detectable helper and wild type virus Hum Gene Ther 1999 10: 1031–1039
Wistuba A et al. Subcellular compartmentalization of AAV-2 assembly J Virol 1997 71: 1341–1352
Acknowledgements
We would like to thank the following individuals for kindly providing gene constructs and plasmids: the human enkephalin promoter was provided by Dr M Comb; the NF promoters were donated by Dr J-P Julien; the human nAChR promoter was donated by Drs A Bessis and J-P Changeux at Institut Pasteur; and the human EF promoter was donated by Dr A Shibui. We would also like to thank S McPhee for his help with the digital images.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Xu, R., Janson, C., Mastakov, M. et al. Quantitative comparison of expression with adeno-associated virus (AAV-2) brain-specific gene cassettes. Gene Ther 8, 1323–1332 (2001). https://doi.org/10.1038/sj.gt.3301529
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3301529
Keywords
This article is cited by
-
Prospects for gene replacement therapies in amyotrophic lateral sclerosis
Nature Reviews Neurology (2023)
-
Combinatorial gene therapy for epilepsy: Gene sequence positioning and AAV serotype influence expression and inhibitory effect on seizures
Gene Therapy (2023)
-
An efficient rAAV vector for protein expression in cortical parvalbumin expressing interneurons
Scientific Reports (2022)
-
MeCP2 gates spatial learning-induced alternative splicing events in the mouse hippocampus
Molecular Brain (2020)
-
Reduction of advanced tau-mediated memory deficits by the MAP kinase p38γ
Acta Neuropathologica (2020)